Digital avatars, AI safety talks and pandemic vaccine equity: UK innovation’s new frontiers

The avatar economy: when dead artists perform again

A £15m funding round for London-based startup Unit1 has reignited debates about the ethical and commercial boundaries of digital resurrection. The company, founded by former Andrew Lloyd Webber Group CEO Barney Wragg, aims to recreate live performances using "hyper-realistic" avatars of musicians—both living and deceased. Investors include Balderton Capital, an early backer of Spotify, signalling serious interest in what Unit1 calls a "lower-cost alternative" to productions like Abba Voyage.

The technology raises immediate questions about consent, copyright, and the commodification of artistic legacy. While Unit1 has not disclosed which artists it plans to digitise, the music industry has long grappled with posthumous rights. In 2025, a UK court ruled that holographic performances of deceased musicians required explicit permission from estates—a precedent that could complicate Unit1’s ambitions. The startup’s pitch—that venues could host "iconic" shows without the logistical hurdles of touring—also ignores the economic realities of an industry where live performance remains the primary revenue stream for most artists.

For the UK, the stakes are higher than nostalgia. The country’s creative industries contribute £116bn annually to the economy, and the government has positioned "immersive tech" as a growth sector. But as the Unit1 case shows, innovation here collides with cultural sensitivities. The Department for Digital, Culture, Media and Sport (DCMS) has yet to clarify whether digital avatars fall under existing performer rights legislation, leaving a regulatory grey zone that could deter investment—or invite exploitation.

AI safety: the US-China détente that could reshape global rules

Ahead of this week’s Trump-Xi summit in New York, US and Chinese officials held rare bilateral talks on artificial intelligence safety—a development with significant implications for the UK’s own regulatory approach. The discussions, described by both sides as "constructive," focused on risk mitigation in military and civilian applications, including export controls on high-performance AI chips.

The timing is critical. The UK has spent 2026 positioning itself as a bridge between Washington and Beijing on tech governance, hosting the AI Safety Summit in March and pushing for a "third way" between outright bans and laissez-faire development. But the US-China dialogue threatens to sideline London. If the two superpowers agree on common standards—even informally—the UK may face pressure to align with rules it didn’t help shape.

Domestically, the talks have already sparked debate. The Labour government’s AI Safety Institute has warned that "fragmented regulation" could leave UK firms at a competitive disadvantage, while civil liberties groups argue that any US-China accord risks embedding surveillance-friendly frameworks. The Institute for Government, a London-based think tank, noted in a September report that "the UK’s influence on global AI governance is inversely proportional to the speed of US-China cooperation."

For now, the details of the New York talks remain sparse. But the mere fact of their occurrence suggests a shift in the geopolitical landscape—one that could force the UK to choose between being a rule-maker or a rule-taker in the decade’s defining technology.

Pandemic preparedness: the vaccine equity paradox

A new study published by the National University of Singapore and The Lancet has exposed the brutal calculus of global vaccine distribution. Modelling a hypothetical flu pandemic, researchers found that sharing doses based on population size—rather than purchasing power—could save 2.7 million additional lives worldwide. But the catch is stark: under this "equitable" model, deaths in high-income countries would rise by 12%.

The findings arrive as the UK prepares to update its pandemic preparedness strategy, with a White Paper expected in early 2027. The current plan, last revised in 2023, prioritises domestic stockpiling and rapid vaccine development—a posture that aligns with the study’s "selfish" scenario. But the research challenges the moral and practical foundations of this approach. As Dr. Jeremy Lim, co-author of the study, told The Guardian, "Pandemics don’t respect borders. A delayed response in one country guarantees a prolonged crisis for all."

The UK’s position is complicated by its role in global health. The country hosts the headquarters of Gavi, the Vaccine Alliance, and has historically been a major funder of COVAX, the WHO-backed initiative for equitable vaccine access. Yet Brexit has weakened its influence in EU-wide health policy, and the government’s 2025 decision to cut overseas aid by £2.9bn has strained diplomatic relationships with low-income nations.

For British policymakers, the study presents an uncomfortable truth: vaccine equity isn’t just an ethical imperative—it’s a strategic one. The UK’s own pandemic resilience depends on the resilience of the global supply chain, from raw materials to manufacturing capacity. As the study’s authors note, "The next pandemic won’t wait for us to decide whether solidarity is affordable."

What’s next: the innovation agenda for 2027

These three developments—a commercial push into digital avatars, the US-China AI safety dialogue, and the vaccine equity debate—highlight the UK’s precarious position in the innovation landscape. Each case forces a choice between economic opportunity and ethical responsibility, between global leadership and domestic priorities.

The government’s forthcoming Innovation Strategy, due in November, will need to address these tensions. Key questions include:

• Digital legacy: Will the UK lead on posthumous performer rights, or leave the field to jurisdictions with looser regulations?
• AI governance: Can London maintain its "bridge" role if Washington and Beijing reach a bilateral deal?
• Health security: Is the UK prepared to accept higher domestic risks for the sake of global resilience?

For now, the answers remain elusive. But one thing is clear: in 2026, innovation is no longer just about technology. It’s about the rules we choose to govern it—and the values we embed in those rules.